1. Market Research
  2. > Pharmaceutical Market Trends
High Potency APIs /HPAPI Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

High Potency APIs /HPAPI Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

  • March 2022
  • 146 pages
  • ID: 6246255
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The High Potency APIs /HPAPI Market is projected to register a CAGR of 8.5% during the forecast period.

During the COVID 19 pandemic, the High Potency APIs /HPAPI Market was adversely affected. COVID 19 primarily affected the supply chain of the API market. Since Southeast Asia (specifically China and India) is the hub for the production of API, the market was severely hampered as COVID increased in this region. According to the Germany Trade & Invest (GTAI) around 60% of APIs including high potency APIs of the world are manufactured either in India or China. India alone accounts for 18% of the global generic drug manufacturing market, most of which is exported to other countries. China is also not only a major manufacturing location itself but also produces 70% of the APIs including high potency APIs for India’s generics industry. This situation makes these two countries the biggest players in the global market for generic medicines. However, these countries also were one of the most affected by the pandemic. As the virus spread globally, India temporarily placed an export curb on 26 drugs and various High potent APIs – which account for around 10% of the country’s pharmaceutical exports – to avoid domestic shortages. This further fueled the adversity in the market. Due to this, the market is adversely affected by the COVID 19. However, various APIs are used in the production of COVID 19 vaccines. Overall, the market would be hindered for short-term durations however, the market will grow significantly once the industry reinforces its supply chain with modern advancements and protocols.

Certain factors that are driving the market growth include increasing demand for drugs (oncology and antibody-drug conjugates), increasing focus on precision medicine and high potency APIs, and technological advancements in high potency API manufacturing. International Agency for Research on Cancer (IARC) updated Globocan 2020 with new estimates about the global cancer burden, which indicates that it has risen to 19.3 million cases and 10 million cancer deaths in 2020. This new study suggests that more than 50 million people are living within 5 years with a cancer diagnosis. Some of the common factors for increasing cancer cases globally are aging populations and socio-economic risk factors. For instance, United States Center for Drug Evaluation and Research (CDER’s) has approved new therapies in 2020 for a wide array of cancers, particularly lung cancers, thyroid cancers, and breast cancers. These therapies include small molecules and large molecules for treatments. High potency APIs are the primary constituents of these drugs. With the growing number of cancer cases, the market will simultaneously grow to provide solutions for the disease. Similarly, according to Parkinson’s foundation around 60,000 Americans are diagnosed with Parkinson’s disease each year Additionally, there is a focus on precision medicine in past few years. As not every patient will respond to the same drug, in the same way, it is required to have a personalized medicine to have higher efficacy. These generic drugs are known as pharmacogenetic. In 2020, United States Food and Drug Administration lists around marker information relating to 200 pharmacogenetic drugs. Similarly, in the United Kingdom, the National Health Scheme aiming to integrate genomic medicines into its routine care by 2025. Due to the aforementioned factors, the tracked market is estimated to witness a healthy growth rate during the forecasted period.

Key Market Trends

Generic High-Potency Active Pharmaceutical Ingredients Segment is Expected to Hold Significant Growth

The High Potency APIs /HPAPI Market is broadly segmented into innovative high-potency active pharmaceutical ingredients and generic high-potency active pharmaceutical ingredients. The primary factor for the growth is the patent expiration of various drugs and increasing demand for cancer treatment combining with the huge cancer treatment drug and pipeline for upcoming years as mentioned above. According to the report published by the American Journal of Managed Care in June 2021, by the year 2023, patents of around 20 oncology biologics will expire, which would lead to the production of more biosimilars in cancer care and therefore reduced costs. According to Roche, Drugs such as Rituxan (a drug for blood cancer) are already facing competition due to the loss of its patent in 2018. Loss of patents leads to low manufacturing costs which leads to more competition, thus propelling the market growth. Due to these reasons, the market will see a high growth period during the forecast period.

North America is Expected to Hold a Major Share in the Market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The United States is the most affected country across the world, with the prevalence of disorders such as cancer, neurological disorder, etc. As these disorders are increasing in the past few years to provide the solution for the same the production of high potency APIs is also increasing in the region. As the High potency APIs are widely used in many therapeutic, drug discovery, or other research related to oncology as well other major disorders. Thus, the demand for the same will be significantly higher in the North American region as the patient population is increasing compared to other countries.

North America is expected to hold a major market share in the global High Potency APIs /HPAPI Market due to the rise in the geriatric population, increasing prevalence and incidence of infectious diseases in this region. The incidence of chronic diseases, like cancer, is also high in the United States. As per the 2020 report by the American Cancer Society journal, there were an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in 2020. In addition, as per a 2018 report by the Center for Disease Control and Prevention, there are around 60% of Americans are living with at least one chronic disease and chronic diseases are the leading causes of death and disability in America. Additionally, according to the Parkinson’s foundation, around 1 million people in the United States are living with Parkinson’s disease, which is more than the combined number of people diagnosed with muscular dystrophy, multiple sclerosis, and Amyotrophic Lateral Sclerosis. This is expected to rise to 1.2 million by 2030. Similarly, in Canada in 2020, around 225,800 new cancer cases and 83,300 cancer deaths are found. Around 30% of all deaths are caused by cancer alone in Canada. However, Canada has a universal healthcare system for its citizens. Due to this, healthcare is accessible to all. This creates an evenly demand in the region. Due to this, the market has had positive growth during the forecast period.

Moreover, the increase in research and development activities and the presence of favorable healthcare infrastructure are fueling the growth of the overall regional market. ?

Competitive Landscape

The High Potency APIs /HPAPI Market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Thermo Fisher Scientific, Inc, Merck KGaA, Pfizer, Novartis International Ag, and Teva Pharmaceutical Industries.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Exosome Research Market by Product and services, Indication, Application, Manufacturing Services, End User - Global Forecast to 2026

  • $ 4950
  • April 2022
  • 183 pages

The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding ...

  • World
  • North America
  • Healthcare
  • In Vitro Diagnostics
  • Industry analysis
  • Cancer Incidence
  • Disposable Income

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on